From March 28 to 29, 2026, the "2026 Bay Area Symposium on Biopharmaceutical Industry Development & The 4th Truth-Seeking Forum on Cell and Gene Industry Development" was grandly held at The Langham, Shenzhen Futian. Co-organized by the Shenzhen Biopharmaceutical Promotion Association and the Cell & Gene Industry Alliance, the event was supported by Peking University Shenzhen Graduate School, Tsinghua Shenzhen International Graduate School, and ICBC Shenzhen Branch. The forum convened scholars, industry leaders, and investment representatives from the Guangdong-Hong Kong-Macao Greater Bay Area and across China to engage in in-depth discussions on frontier trends, policy landscapes, and translational pathways. Shenzhen Cell Valley Biopharmaceutical Co., Ltd. was invited to attend and was honored with the "CGT Leading Enterprise" award for 2025.

The biopharmaceutical industry is currently ushering in a new wave of strategic development opportunities. The 2026 Government Work Report explicitly listed biomedicine as a "new emerging pillar industry" at the national level. Coupled with the accelerating global expansion of innovative drugs, the rapid commercialization of cutting-edge technologies, and the continuous optimization of uation, approval, and payment policies, the industry is entering a new phase driven by "pillar status, globalization, and technological revolution." Against this backdrop, the forum focused on the frontier trends and industrialization pathways of Cell and Gene Therapy (CGT), establishing a vital platform for collaborative innovation and high-quality development.

During the awards ceremony on the morning of March 29, Shenzhen Cell Valley received the "CGT Leading Enterprise" award from the Shenzhen Biopharmaceutical Promotion Association. The company was recognized for its outstanding performance in independent core technology innovation, the construction of full-chain public service platforms, large-scale clinical translation, and industrial ecosystem synergy. As one of the most influential accolades in the field, the award honors benchmark enterprises that demonstrate excellence in core technologies and industrial leadership. This recognition fully reflects the industry's high regard for Shenzhen Cell Valley's comprehensive strength and development potential.

Following the award presentation, Professor Wang Jianxun, Chief Scientist of Cell Valley Group, delivered a keynote speech titled "CGT Public Service Platforms Empowering High-Quality IIT Development." Professor Wang noted that with the successive implementation of State Council Decrees No. 818 and No. 828, China's CGT sector is rapidly forming a dual-track governance landscape that synergizes "biomedical new technologies" with "pharmaceutical regulation." He explained that Decree No. 818 systematically regulates clinical research and translation, while Decree No. 828 further refines the lifecycle supervision of pharmaceuticals. These complementary policies not only solidify compliance baselines but also open clearer pathways for innovation, pushing the industry toward standardized, high-quality development.

Addressing industry practices, Professor Wang analyzed that Investigator-Initiated Trials (IIT) currently face bottlenecks such as insufficient production standardization, quality control challenges, and low resource synergy efficiency. To address these pain points, Shenzhen Cell Valley has established an open CGT public service platform. Leveraging industrial-grade viral vector production technology and a mature cell product development system, the company has built a full-chain service system covering vector development, manufacturing, and quality compliance, providing standardized and practical support for IIT projects.

Professor Wang also highlighted the company's recent achievements. Shenzhen Cell Valley has established deep clinical research collaborations with over 100 top-tier hospitals nationwide, facilitating the filing of more than 100 IIT projects. Notably, over 30 IITs and international clinical trials (NCT) have been successfully approved, providing robust support for clinical validation in hematology and solid tumors. Through a model of "technology sharing, resource synergy, and platform empowerment," the company continues to accelerate the journey of innovative therapies from the lab to the patient.

The forum served not only as a window for high-level exchange in the Bay Area but also injected new momentum into the collaborative innovation of the CGT industry. Professor Wang affirmed that Cell Valley will continue to deepen core R&D, refine its public service platforms, and actively participate in ecosystem building to contribute greater strength to China's biopharmaceutical development.